{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:15:53Z","timestamp":1775182553559,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017B020227004, 2017A030313538"],"award-info":[{"award-number":["2017B020227004, 2017A030313538"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81725016, 81872094, 81772718, 81602219, 81972376"],"award-info":[{"award-number":["81725016, 81872094, 81772718, 81602219, 81972376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Big Data"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Gene expression profiles and clinical information of 1216 BCa patients were extracted from TCGA-BLCA, three GEO databases and IMvigor210 cohort. We comprehensively established the FeME landscape of 1216 BCa samples based on 290 ferroptosis related genes (FRGs), and systematically correlated these regulation patterns with TME cell-infiltrating characteristics. Besides, we identified the patients\u2019 ferroptosis risk index (FRI) to predict the prognosis of BCa for precise treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six over-expressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in BCa. Furthermore, we demonstrated the evaluation of FeME within individual tumors could predict stages of tumor inflammation, subtypes, genetic variation, and patient prognosis. Then, 5-lncRNA signature was mined to produce the FRI. Low FRI was also linked to increased mutation load, better prognosis and enhanced response to anti-PD-L1 immunotherapy. Besides, an immunotherapy cohort confirmed patients with lower FRI demonstrated significant therapeutic advantages and clinical benefits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TFRC, SCD, G6PD, FADS2, SQLE, and SLC3A2 are potent antigens for developing anti-BCa mRNA vaccine. Establishment of FRI will contribute to enhancing our cognition of TME infiltration characterization and guiding more effective immunotherapy strategies and selecting appropriate patients for tumor vaccine therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40537-022-00641-z","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:02:53Z","timestamp":1657170173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer"],"prefix":"10.1186","volume":"9","author":[{"given":"Cheng-Peng","family":"Gui","sequence":"first","affiliation":[]},{"given":"Jia-Ying","family":"Li","sequence":"additional","affiliation":[]},{"given":"Liang-Min","family":"Fu","sequence":"additional","affiliation":[]},{"given":"Cheng-Gong","family":"Luo","sequence":"additional","affiliation":[]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Yi-Ming","family":"Tang","sequence":"additional","affiliation":[]},{"given":"Li-zhen","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Guan-nan","family":"Shu","sequence":"additional","affiliation":[]},{"given":"Rong-Pei","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Jun-Hang","family":"Luo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"641_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404\u201323.","journal-title":"CA Cancer J Clin"},{"key":"641_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"641_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35:2117\u201324.","journal-title":"J Clin Oncol"},{"key":"641_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322.","journal-title":"Lancet Oncol"},{"key":"641_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S. Dinutuximab: first global approval. Drugs. 2015;75:923\u20137.","journal-title":"Drugs"},{"key":"641_CR6","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1172\/JCI128437","volume":"129","author":"P Weitzenfeld","year":"2019","unstructured":"Weitzenfeld P, Bournazos S, Ravetch JV. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J Clin Invest. 2019;129:3952\u201362.","journal-title":"J Clin Invest"},{"key":"641_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/08830180600992423","volume":"25","author":"LA Emens","year":"2006","unstructured":"Emens LA. Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol. 2006;25:415\u201343.","journal-title":"Int Rev Immunol"},{"key":"641_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102890","author":"EJ Sayour","year":"2018","unstructured":"Sayour EJ, Mendez-Gomez HR, Mitchell DA. Cancer vaccine immunotherapy with RNA-loaded liposomes. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19102890.","journal-title":"Int J Mol Sci"},{"key":"641_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107\u201325.","journal-title":"Cell Res"},{"key":"641_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270\u20134.","journal-title":"Nature"},{"key":"641_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/15548627.2020.1714209","volume":"16","author":"E Dai","year":"2020","unstructured":"Dai E, Han L, Liu J, Xie Y, Kroemer G, Klionsky DJ, Zeh HJ, Kang R, Wang J, Tang D. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16:2069\u201383.","journal-title":"Autophagy"},{"key":"641_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-immunol-041015-055459","volume":"35","author":"MK Atianand","year":"2017","unstructured":"Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017;35:177\u201398.","journal-title":"Annu Rev Immunol"},{"key":"641_CR13","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/0008-5472.CAN-17-3454","volume":"78","author":"C Mao","year":"2018","unstructured":"Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, Shi Y, Shen Y, Liu X, Lai W, Yang R, Xiao D, Cheng Y, Liu S, Zhou H, Cao Y, Yu W, Muegge K, Yu H, Tao Y. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Res. 2018;78:3484\u201396.","journal-title":"Cancer Res"},{"key":"641_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Senbabaoglu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Hoglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"641_CR15","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"641_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/0019-5154.182416","volume":"61","author":"A Hazra","year":"2016","unstructured":"Hazra A, Gogtay N. Biostatistics series module 3: comparing groups: numerical variables. Indian J Dermatol. 2016;61:251\u201360.","journal-title":"Indian J Dermatol"},{"key":"641_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"641_CR18","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310.","journal-title":"Cancer Res"},{"key":"641_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3758\/s13428-013-0329-y","volume":"45","author":"ME Timmerman","year":"2013","unstructured":"Timmerman ME, Ceulemans E, De Roover K, Van Leeuwen K. Subspace K-means clustering. Behav Res Methods. 2013;45:1011\u201323.","journal-title":"Behav Res Methods"},{"key":"641_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133.","journal-title":"Bioinformatics"},{"key":"641_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"641_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47.","journal-title":"Nucleic Acids Res"},{"key":"641_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jnci\/djj052","volume":"98","author":"C Sotiriou","year":"2006","unstructured":"Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262\u201372.","journal-title":"J Natl Cancer Inst"},{"key":"641_CR24","first-page":"737","volume":"7","author":"D Zeng","year":"2019","unstructured":"Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, Bin J, Liao Y, Rao J, Liao W. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures, cancer. Immunol Res. 2019;7:737\u201350.","journal-title":"Immunol Res"},{"key":"641_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.","journal-title":"BMC Bioinformatics"},{"key":"641_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13567","volume":"204","author":"A Hajiran","year":"2021","unstructured":"Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mule J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021;204:96\u2013106.","journal-title":"Clin Exp Immunol"},{"key":"641_CR27","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"641_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.smim.2017.12.002","volume":"35","author":"C Qian","year":"2018","unstructured":"Qian C, Cao X. Dendritic cells in the regulation of immunity and inflammation. Semin Immunol. 2018;35:3\u201311.","journal-title":"Semin Immunol"},{"key":"641_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"641_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15:669\u201382.","journal-title":"Nat Rev Immunol"},{"key":"641_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","volume":"25","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25:268\u201376.","journal-title":"Curr Opin Immunol"},{"key":"641_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","volume":"42","author":"TF Gajewski","year":"2015","unstructured":"Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol. 2015;42:663\u201371.","journal-title":"Semin Oncol"},{"key":"641_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380.","journal-title":"Science"},{"key":"641_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122:899\u2013910.","journal-title":"J Clin Invest"},{"key":"641_CR35","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS. Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492\u2013504.","journal-title":"Ann Oncol"},{"key":"641_CR36","doi-asserted-by":"publisher","first-page":"11318","DOI":"10.1111\/jcmm.15713","volume":"24","author":"N Li","year":"2020","unstructured":"Li N, Li J, Mi Q, Xie Y, Li P, Wang L, Binang H, Wang Q, Wang Y, Chen Y, Wang Y, Mao H, Du L, Wang C. Long non-coding RNA ADAMTS9-AS1 suppresses colorectal cancer by inhibiting the Wnt\/beta-catenin signalling pathway and is a potential diagnostic biomarker. J Cell Mol Med. 2020;24:11318\u201329.","journal-title":"J Cell Mol Med"},{"key":"641_CR37","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/s41388-021-01743-3","volume":"40","author":"Y Chen","year":"2021","unstructured":"Chen Y, Cheng WY, Shi H, Huang S, Chen H, Liu D, Xu W, Yu J, Wang J. Classifying gastric cancer using FLORA reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis. Oncogene. 2021;40:2898\u2013909.","journal-title":"Oncogene"},{"key":"641_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016437","volume":"98","author":"Y Sun","year":"2019","unstructured":"Sun Y, Ling C. Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer. Medicine. 2019;98: e16437.","journal-title":"Medicine"},{"key":"641_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/jcp.29871","volume":"236","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Zhang H, Li W, Yan Y, Yao X, Gu W. LINC01426 contributes to clear cell renal cell carcinoma progression by modulating CTBP1\/miR-423-5p\/FOXM1 axis via interacting with IGF2BP1. J Cell Physiol. 2021;236:427\u201339.","journal-title":"J Cell Physiol"},{"key":"641_CR40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.omtm.2020.08.001","volume":"18","author":"B Tian","year":"2020","unstructured":"Tian B, Han X, Li G, Jiang H, Qi J, Li J, Tian Y, Wang C. A long intergenic non-coding RNA, LINC01426, promotes cancer progression via AZGP1 and predicts poor prognosis in patients with LUAD. Mol Ther Methods Clin Dev. 2020;18:765\u201380.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"641_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jcmm.15980","volume":"25","author":"X Li","year":"2021","unstructured":"Li X, Jin F, Li Y. A novel autophagy-related lncRNA prognostic risk model for breast cancer. J Cell Mol Med. 2021;25:4\u201314.","journal-title":"J Cell Mol Med"},{"key":"641_CR42","first-page":"6676692","volume":"2021","author":"R Xiao","year":"2021","unstructured":"Xiao R, Yang M, Tan Y, Ding R, Li D. Identification of five immune-related lncRNAs predicting survival and tumor microenvironment characteristics in breast cancer. Comput Math Methods Med. 2021;2021:6676692.","journal-title":"Comput Math Methods Med"},{"key":"641_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ng.3465","volume":"48","author":"HH Jabara","year":"2016","unstructured":"Jabara HH, Boyden SE, Chou J, Ramesh N, Massaad MJ, Benson H, Bainter W, Fraulino D, Rahimov F, Sieff C, Liu ZJ, Alshemmari SH, Al-Ramadi BK, Al-Dhekri H, Arnaout R, Abu-Shukair M, Vatsayan A, Silver E, Ahuja S, Davies EG, Sola-Visner M, Ohsumi TK, Andrews NC, Notarangelo LD, Fleming MD, Al-Herz W, Kunkel LM, Geha RS. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet. 2016;48:74\u20138.","journal-title":"Nat Genet"},{"key":"641_CR44","first-page":"131","volume":"10","author":"Y Huang","year":"2020","unstructured":"Huang Y, Huang J, Huang Y, Gan L, Long L, Pu A, Xie R. TFRC promotes epithelial ovarian cancer cell proliferation and metastasis via up-regulation of AXIN2 expression. Am J Cancer Res. 2020;10:131\u201347.","journal-title":"Am J Cancer Res"},{"key":"641_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41419-020-02859-2","volume":"11","author":"S Han","year":"2020","unstructured":"Han S, Wang Y, Ma J, Wang Z, Wang HD, Yuan Q. Sulforaphene inhibits esophageal cancer progression via suppressing SCD and CDH3 expression, and activating the GADD45B-MAP2K3-p38-p53 feedback loop. Cell Death Dis. 2020;11:713.","journal-title":"Cell Death Dis"},{"key":"641_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.molcel.2019.10.014","volume":"77","author":"Y Vivas-Garcia","year":"2020","unstructured":"Vivas-Garcia Y, Falletta P, Liebing J, Louphrasitthiphol P, Feng Y, Chauhan J, Scott DA, Glodde N, Chocarro-Calvo A, Bonham S, Osterman AL, Fischer R, Ronai Z, Garcia-Jimenez C, Holzel M, Goding CR. Lineage-restricted regulation of SCD and fatty acid saturation by MITF controls melanoma phenotypic plasticity. Mol Cell. 2020;77:120-137 e129.","journal-title":"Mol Cell"},{"key":"641_CR47","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1111\/jcmm.14241","volume":"23","author":"HS Zhang","year":"2019","unstructured":"Zhang HS, Zhang ZG, Du GY, Sun HL, Liu HY, Zhou Z, Gou XM, Wu XH, Yu XY, Huang YH. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD\/HIF-1alpha\/Notch1 axis. J Cell Mol Med. 2019;23:3451\u201363.","journal-title":"J Cell Mol Med"},{"key":"641_CR48","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1158\/0008-5472.CAN-19-2389","volume":"80","author":"J Tian","year":"2020","unstructured":"Tian J, Lou J, Cai Y, Rao M, Lu Z, Zhu Y, Zou D, Peng X, Wang H, Zhang M, Niu S, Li Y, Zhong R, Chang J, Miao X. Risk SNP-mediated enhancer-promoter interaction drives colorectal cancer through both FADS2 and AP002754.2. Cancer Res. 2020;80:1804\u201318.","journal-title":"Cancer Res"},{"key":"641_CR49","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.7150\/thno.19988","volume":"7","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, Lai W, Liu Y, Wang X, Xiao D, Zhou H, Cheng Y, Yu F, Cao Y, Liu S, Yan Q, Tao Y. EGLN1\/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics. 2017;7:3293\u2013305.","journal-title":"Theranostics"},{"key":"641_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188394","volume":"1874","author":"H Xu","year":"2020","unstructured":"Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874: 188394.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"641_CR51","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1080\/15548627.2019.1639302","volume":"15","author":"D Digomann","year":"2019","unstructured":"Digomann D, Linge A, Dubrovska A. SLC3A2\/CD98hc, autophagy and tumor radioresistance: a link confirmed. Autophagy. 2019;15:1850\u20131.","journal-title":"Autophagy"},{"key":"641_CR52","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Canellas A, Hernando-Momblona X, Byrom D, Matarin JA, Calon A, Rivas EI, Nebreda AR, Riera A, Attolini CS, Batlle E. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343.","journal-title":"Nature"}],"container-title":["Journal of Big Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40537-022-00641-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40537-022-00641-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40537-022-00641-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T06:12:52Z","timestamp":1657174372000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalofbigdata.springeropen.com\/articles\/10.1186\/s40537-022-00641-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1186\/s40537-022-00641-z","relation":{},"ISSN":["2196-1115"],"issn-type":[{"value":"2196-1115","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}